Blood test may spot liver cancer risk years early in cirrhosis patients

NCT ID NCT06778317

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The goal is to catch liver cancer earlier and tailor screening to those who need it most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mSEPT9 blood test
What this could lead to
If successful, this blood test could help doctors identify cirrhosis patients at highest risk for liver cancer, allowing for earlier detection and personalized monitoring.
What could go wrong
This is an observational study, not a treatment trial. The test may not accurately predict cancer in all patients, and results may not change outcomes. Further studies would be needed to confirm its usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Regional and University Hospital Center of Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.